Based on our previous phase I clinical trials, both prophylactic and therapeutic with the vaccine MVA-B where moderate T cell immune responses were induced, the results reported here suggest that the combination of TMEP vectors together with MVA-B should help to further expand the HIV-1-specific CD8 T cell immune responses in vaccinees, a process which might be beneficial to control HIV-1 infections, particularly in those individuals under cART-treatment. Here, CD8A is linked to HIV-1 infection.